ESC 365 - Benefit-harm trade-offs of intensive blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of six pivotal randomized controlled trials.

ESC Professional Premium Access

Benefit-harm trade-offs of intensive blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of six pivotal randomized controlled trials.

Session: Late-Breaking Clinical Science: new treatments and biomarkers in hypertension

Topic: Clinical

Speaker: Doctor X. Guo (Shenyang, CN)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Xiaofan Guo

The First Affiliated Hospital of China Medical University, Shenyang (China)

1 presentation

0 follower

3 more presentations in this session

Duration of blood pressure treatment and risk of major cardiovascular events

Speaker: Professor K. Rahimi (Oxford, GB)

ADEL: A population-based study of clinical outcomes of aldosterone dysregulation

Speaker: Professor R. Thomsen (Aarhus, DK)

Sacubitril/Allisartan in hyperuricemia

Speaker: Doctor W. Zhang (Shanghai, CN)

Access the full session

Late-Breaking Clinical Science: new treatments and biomarkers in hypertension

Speakers: Doctor X. Guo, Professor K. Rahimi, Professor R. Thomsen, Doctor W. Zhang

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources